PolyPid Ltd. Ordinary Shares (PYPD)
Stock · NASDAQ · Health Care
$4.75as of 10/16/2026
Price chart
Active signals
PYPD Signal Track Record
How signals performed across all stocks →What PYPD's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 23 | +0.9% | 61% | October 2, 2026 |
| Bollinger Band Breakdown | 22 | +3.0% | 59% | October 7, 2026 |
| Bollinger Band Breakout | 21 | -1.1% | 48% | September 22, 2026 |
| 200-Day Moving Average TouchActive now | 3 | +15.9% | 67% | July 30, 2026 |
| Any 20-session window (baseline) | -1.9% | 42% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PYPD
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 69
- Website
- www.polypid.com
Fundamentals
- 1-day range
- $4.72$4.9
- Market cap
- $91.79M
- P/E (trailing)
- —
- P/E (forward)
- -3.85
- EPS (trailing)
- $-1.48
- Dividend yield
- —
- Beta
- 1.48
- Avg. volume
- 167.7K
Forecasts
4 analyst ratings
PolyPid Ltd. Ordinary Shares Competitors
Chosen by industry and closest market cap.
- PYPDPolyPid Ltd. Ordinary Shares$4.72▼ 3.67%Market cap $91.79MP/E —$3.1$5.73
- LUNGPulmonx Corporation Common Stock$1.78▼ 3.78%Market cap $88.04MP/E —$1.13$2.89
- SKINSkinHealth Systems Inc. Class A Common Stock$10.56▼ 16.19%Market cap $99.91MP/E —$10.01$34.8
- GUTSFractyl Health Inc. Common Stock$1.55▼ 62.74%Market cap $108.99MP/E —$3.78$29.34
- LNSRLENSAR Inc. Common Stock$5.8▼ 3.81%Market cap $70.43MP/E 2.15$4.95$12.94
- MBOTMicrobot Medical Inc. Common Stock$0.95▲ 0.00%Market cap $120.90MP/E —$0.99$3.04
- XTNTXtant Medical Holdings Inc. Common Stock$0.29▼ 3.33%Market cap $62.09MP/E 23.84$0.2702$0.95
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PYPD PolyPid Ltd. Ordinary Shares | $91.79M | — | $4.72 | ▼ 3.67% | $3.1$5.73 |
| LUNG Pulmonx Corporation Common Stock | $88.04M | — | $1.78 | ▼ 3.78% | $1.13$2.89 |
| SKIN SkinHealth Systems Inc. Class A Common Stock | $99.91M | — | $10.56 | ▼ 16.19% | $10.01$34.8 |
| GUTS Fractyl Health Inc. Common Stock | $108.99M | — | $1.55 | ▼ 62.74% | $3.78$29.34 |
| LNSR LENSAR Inc. Common Stock | $70.43M | 2.15 | $5.8 | ▼ 3.81% | $4.95$12.94 |
| MBOT Microbot Medical Inc. Common Stock | $120.90M | — | $0.95 | ▲ 0.00% | $0.99$3.04 |
| XTNT Xtant Medical Holdings Inc. Common Stock | $62.09M | 23.84 | $0.29 | ▼ 3.33% | $0.2702$0.95 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- PolyPid Nears FDA Decision for D-PLEX100 After Strong Phase III DataYahoo · 10/4/2026
- European Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-PLEX₁₀₀Yahoo · 10/1/2026
- PolyPid Agrees With ADVANZ PHARMA To Terminate Their 2022 Exclusive License, Distribution And Supply Agreement For D-PLEX₁₀₀ In Europebenzinga · 10/1/2026
- PolyPid Regains European Commercialization Rights for D-PLEX₁₀₀, Expanding Global Commercialization OpportunitiesYahoo · 10/1/2026
- PolyPid Agrees With ADVANZ PHARMA To Terminate Their 2022 Exclusive License, Distribution And Supply Agreement For D-PLEX₁₀₀ In EuropeBenzinga · 10/1/2026
- PolyPid Announces Participation in Upcoming Fall Investor ConferencesYahoo · 9/15/2026
Insider Activity
Insider Actions →- Dror-Darwish Nir · July 15, 2026 · Grant9.1K @ $4.46
- BenAmram Joseph · July 15, 2026 · Grant9.1K @ $4.46
- Story Brooke · July 15, 2026 · Grant9.1K @ $4.46
- Akselbrad Dikla Czaczkes · July 15, 2026 · Grant149.0K @ $4.46
- Stein Robert Benjamin · July 15, 2026 · Grant9.1K @ $4.46
- Krinsky Itzhak · July 15, 2026 · Grant9.1K @ $4.46
- Barenholz Yechezkel · July 15, 2026 · Grant9.1K @ $4.46
- Warshavsky Ori · May 11, 2026 · Grant46.0K @ $4.46
- Missulawin Jonathan · May 11, 2026 · Grant49.0K @ $4.46
- Hazan Dalit Fellous · May 11, 2026 · Grant75.0K @ $4.46
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
PolyPid Ends Exclusive License with AdvanZ Pharma in Europe
PolyPid has agreed to terminate its 2022 exclusive license, distribution, and supply agreement with AdvanZ Pharma for the D‑Plex 100 product in Europe. The decision ends a partnership that had granted PolyPid exclusive rights to market the drug in the region. This change may alter PolyPid’s European sales and supply chain dynamics. The company’s stock is currently trading within its 52‑week range.
PolyPid Ends Exclusive License with AdvanZ Pharma in Europe. PolyPid has agreed to terminate its 2022 exclusive license, distribution, and supply agreement with AdvanZ Pharma for the D‑Plex 100 product in Europe. The decision ends a partnership that had granted PolyPid exclusive rights to market the drug in the region. This change may alter PolyPid’s European sales and supply chain dynamics. The company’s stock is currently trading within its 52‑week range.